<DOC>
	<DOCNO>NCT00283543</DOCNO>
	<brief_summary>To determine safety efficacy Gliadel 3.85 % wafer plus surgery radiation Temozolomide</brief_summary>
	<brief_title>Radiation With Concomitant Then Sequential Temozolomide Malignant Glioma</brief_title>
	<detailed_description>A phase II study radiation concomitant sequential Temozolomide patient newly diagnose supratentorial malignant glioma undergone surgery Gliadel wafer insertion . To determine safety efficacy Gliadel 3.85 % wafer plus surgery limited field radiation therapy concomitant Temozolomide follow Temozolomide alone patient undergo initial surgery newly diagnose unifocal moderate high grade glioma .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>MRI show unilateral supratentorial cerebral tumor surgical tx within 4 week baseline MRI KPS 60 % high moderate high grade malignant glioma prior cytoreductive surgery moderate high grade glioma prior CNS radiotherapy prior chemo glioma one focus tumor tumor cross midline per MRI life expectancy le 12 month sensitivity temozolomide , nitrosoureas , Gliadel wafer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Gliadel Wafer</keyword>
</DOC>